Anti-Mouse CD18 [Clone M18/2] — Purified

Mouse CTL glycoprotein

This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This purified antibody is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2-8° C Wet Ice

M18/2 activity is directed against mouse CD18.

Integrins are a large family of α/β heterodimeric transmembrane molecules that mediate adhesion, migration, cell survival, and cell differentiation¹. The leukocytic cell-adhesion molecule (Leu-CAM) family has three members, LFA-1 (CD18/CD11a), CR3 (also known as MAC-1) (CD18/CD11b), and p150,95 (CD18/CD11c), all of which share the β chain CD18². Depending on which molecule CD18 is bound to, this β chain plays important roles in inflammation, initiation of the immune response, phagocytosis, adherence to endothelium, chemotaxis, and can act as a fibrinogen receptor as part of its heterodimer³.

M18/2 was generated by immunizing rat with mouse cytotoxic T cell glycoproteins and fusing the spleen cells with mouse myeloma line P3X63Ag8.653⁴. M18/2 was selected by immunoprecipitation of LFA-1 and found to bind to the β chain of both LFA-1 and MAC-1. M18/2 has subsequently been used to study lymphoma metastasis^3,5, myelin phagocytosis⁶, platelet caspases and thrombocytosis⁷, and the immunosuppression of corneal allografts⁸.

CD18 is expressed on all leukocytes as well as on myeloid cells.

ICAM-1 (CD54), ICAM-2 (CD102), ICAM-3 (CD50), iC3b, fibrinogen

1 Luo BH, Carman CV, Springer TA. Annu Rev Immunol. 25:619-647. 2007.
2 Sanchez-Madrid F, Nagy JA, Robbins E, et al. J Exp Med. 158(6):1785-1803. 1983.
3 Driessens MH, van Hulten P, Zuurbier A, et al. J Leukoc Biol. 60(6):758-765. 1996.
4 Sanchez-Madrid F, Simon P, Thompson S, et al. J Exp Med. 158(2):586-602. 1983.
5 Zahalka MA, Okon E, Naor D. J Immunol. 150(10):4466-4477. 1993.
6 Reichert F, Rotshenker S. Neurobiol Dis. 12(1):65-72. 2003.
7 Piguet PF, Vesin C. Eur J Haematol. 68(5):253-261. 2002.
8 Hori J, Isobe M, Yamagami S, et al. Exp Eye Res. 65(1):89-98. 1997.